Forecast horizon — calibration-scored at resolution.
By 2028, DBS referral in PD will routinely be considered within 5 years of motor-complication onset (vs. the historical ≥10-year pattern).
TL;DR · AI-generated
Subthalamic stimulation was superior to medical therapy in patients with Parkinson's disease and early motor complications and time with good mobility and no dyskinesia.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Neurostimulation for Parkinson's Disease with Early Motor Complications
W.M.M. Schuepbach et al. · New England Journal of Medicine · 2013
· openalex W2106956384 · s2 cb543cbd
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1839
The EARLYSTIM trial's stated primary conclusion — Early STN-DBS improves quality of life in Parkinson disease patients with early motor complications vs. medical therapy. — replicates in independent cohorts.
0.2260
By 2028, median door-to-puncture time at thrombectomy centers will meet or beat the ESCAPE benchmark of ≤60 minutes.
0.2275
By 2028, ≥40% of cSDH evacuations at academic centers will include adjunctive MMA embolization.
0.2300
By 2028, flow-diverter use will extend to posterior circulation aneurysms with safety non-inferior to anterior-circulation benchmarks.
0.2329
By 2028, MMA embolization will be incorporated into AANS/CNS guidelines as a recommended adjunct for recurrent cSDH.
0.2332
By 2028, long-term follow-up will show durability of Zolgensma motor benefit plateau at ≥5 years post-infusion in early-treated cohorts.